- Previous Close
1.6900 - Open
1.6500 - Bid 1.2200 x 200
- Ask 2.1200 x 200
- Day's Range
1.6300 - 1.6900 - 52 Week Range
1.5600 - 2.6250 - Volume
232,453 - Avg. Volume
221,771 - Market Cap (intraday)
99.238M - Beta (5Y Monthly) 1.62
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3900 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.00
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
seer.bioRecent News: SEER
View MorePerformance Overview: SEER
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SEER
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SEER
View MoreValuation Measures
Market Cap
101.03M
Enterprise Value
-109.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.55
Price/Book (mrq)
0.31
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.58%
Return on Equity (ttm)
-23.91%
Revenue (ttm)
14.17M
Net Income Avi to Common (ttm)
-86.6M
Diluted EPS (ttm)
-1.3900
Balance Sheet and Cash Flow
Total Cash (mrq)
236.41M
Total Debt/Equity (mrq)
7.93%
Levered Free Cash Flow (ttm)
-32.3M